Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226947 · ClinicalTrials.gov registry record · NA
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
A NA study of Obesity and Body Composition, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07226947: Recruiting NA study of Obesity and Body Composition, sponsored by Massachusetts General Hospital.
NCT07226947 is a NA study of Obesity and Body Composition that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226947, a NA study of Obesity and Body Composition, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Primary Outcome
Dual-energy X-ray absorptiometry (DXA) body composition measure
Conditions Studied
Interventions
- DEVICE Smartwatch activity and body composition monitor
- BEHAVIORAL General guidance on recommended exercise
Study Locations (1)
Massachusetts
- Diabetes Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT07226947 shows while recruiting
NCT07226947 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Smartwatch activity and body composition monitor is the first listed.
NCT07226947 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07226947 about?
NCT07226947 is a clinical study titled "Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment". The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirze...
What is the current status of trial NCT07226947?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-11-24. Estimated completion is 2027-06.
What conditions does trial NCT07226947 study?
This clinical trial studies the following conditions: Obesity, Body Composition.
What interventions are being tested in trial NCT07226947?
The interventions under investigation include: Smartwatch activity and body composition monitor (DEVICE), General guidance on recommended exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT07226947?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226947 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226947's enrollment target sits among peer trials
100 478th of 1053 higher than 555 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
SMARTer Weight Loss Management
RECRUITING · NA
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI